Adherence to the combination of sulphadoxine-pyrimethamine and XXXX in the Maheba refugee settlement, Zambia.

@entity1 @entity1484 @entity507 @entity3964 @entity506 @entity311
@entity507 -based combination therapy (ACT) is one strategy recommended to increase cure rates in @entity311 and to contain resistance to @entity3964 . In the Maheba refugee settlement, @entity1 aged 5 years or younger with a confirmed diagnosis of uncomplicated falciparum @entity311 are treated with the combination of @entity1484 (1 day) and @entity506 (3 days). To measure treatment adherence, home visits were carried out the day after the last treatment dose. @entity1 who had any treatment dose left were considered certainly non-adherent. Other @entity1 ' classification was based on the answers to the questionnaire: @entity1 whose caretakers stated the @entity1 had received the treatment regimen exactly as prescribed were considered probably adherent; all other @entity1 were considered probably non-adherent. Reasons for non-adherence were assessed. We found 21.2% (95% CI [15.0-28.4]) of the @entity1 to be certainly non-adherent, 39.4% (95% CI [31.6-47.6]) probably non-adherent, and 39.4% (95% CI [31.6-47.6]) probably adherent. Insufficient explanation by the dispenser was identified as an important reason for non-adherence. When considering the use of ACT, the issue of @entity1 adherence remains challenging. However, it should not be used as an argument against the introduction of ACT. For these treatment regimens to remain efficacious on a long-term basis, specific and locally adapted strategies need to be implemented to ensure completion of the treatment.
